老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较

doi:10.3969/j.issn.1004-616x.2021.02.007

癌变·畸变·突变 ›› 2021, Vol. 33 ›› Issue (2): 124-128.doi: 10.3969/j.issn.1004-616x.2021.02.007

老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较

焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳

河北医科大学第四医院检验科, 河北石家庄 050011

收稿日期:2020-11-15 修回日期:2021-03-05 出版日期:2021-03-30 发布日期:2021-04-12
通讯作者: 张金艳,E-mail:jinyanzhang66@sina.com E-mail:jinyanzhang66@sina.com
作者简介:焦文静,E-mail:wenjing-79@163.com。
基金资助:
河北省卫生健康委员会基金（20200115）

Comparative efficacies between concurrent chemo-radiotherapy and radiotherapy alone in elderly patients with locally advanced esophageal cancers

JIAO Wenjing, GUO Xiujuan, MA Ming, SHAO Junguo, ZHANG Jinyan

Clinical Laboratory of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China

Received:2020-11-15 Revised:2021-03-05 Online:2021-03-30 Published:2021-04-12

摘要/Abstract

摘要： 目的：比较老年局部晚期食管癌患者采用同步放化疗（CRT）和单纯放疗（RT）的疗效和急性不良反应。方法：回顾性分析2010年1月—2016年1月于河北医科大学第四医院就诊，年龄>70岁的82例老年局部晚期食管癌患者。比较CRT和RT两个治疗组间的完全缓解率（CRR）、部分缓解率（PRR）、疾病缓解率（DCR）、无进展生存期（PFS）、总生存期（OS）和急性不良反应，并分析食管癌预后的影响因素。结果：CRT组患者的CRR （33.3%）明显高于RT组（14.5%，P=0.049），两组之间PRR和DCR的差异无统计学意义（P=0.058，0.064）。CRT组患者的中位PFS及PFS≥1、2、3年的患者比例均显著高于RT组（P=0.007）。CRT组患者的中位OS及OS≥1、2、3年的患者比例亦显著高于RT组（P=0.012）。单因素分析显示不同治疗方案、CRR是PFS和OS的影响因素。多因素分析显示CRR为PFS的独立预后影响因素，不同治疗方案、CRR是OS的独立预后影响因素（均为P <0.05）。CRT组患者的部分急性不良反应有恶心、呕吐、白细胞减少症、血小板减少症，发生率均高于RT组（均为P <0.05）。结论：同步放化疗可作为老年局部晚期食管鳞癌患者的治疗方案，且疗效优于单纯放疗，但仍需密切关注患者的不良反应。

关键词: 老年, 食管癌, 近期疗效, 同步放化疗

Abstract: OBJECTIVE: To compare efficacies and acute toxicity between concurrent chemo-radiotherapy (CRT) and radiotherapy alone (RT) among elderly patients with locally advanced esophageal cancers. METHODS: Patients who were aged >70 years and who had locally advanced esophageal cancers were recruited from the Fourth Hospital of Hebei Medical University from 2010.1 to 2016.1. Patients' complete response rates (CRR),partial response rates (PRR),disease control rates (DCR),as well as progression-free survival (PFS),overall survival (OS) and acute adverse reactions were evaluated and followed by analysis of prognostic factors. RESULTS: 82 patients were recruited for our study. The CRR in the CRT group (33.3%) was significantly higher than that in the RT group (14.5%,P=0.049). There was no significant difference in PRR and DCR between the two groups. (P=0.058,0.064). The median PFS and the proportion of patients with PFS ≥ 1,2,and 3 years in the CRT group was significantly higher than that in the RT group(P=0.007). The median OS and the proportion of patients with OS ≥ 1,2,and 3 years in the CRT group was significantly higher than that in the RT group (P=0.012). Analysis of Univariants data show that different treatment options and CRR after treatment mainly affected PFS and OS. Multivariate analyses show that CRR was an independent prognostic factor for PFS,treatment plan and CRR were independent prognostic factor for OS (all P<0.05). Some acute adverse reactions in the CRT group:including nausea and vomiting,leukopenia,thrombocytopenia,were significantly more frequent than the RT group(all P<0.05). CONCLUSION: Chemo-radiotherapy can be used as a treatment option for elderly patients with locally advanced esophageal squamous cell carcinoma,and its efficacy was better than that of radiotherapy alone. During the treatment process,close attention should be paid to patients' adverse reactions.

Key words: elderly, esophageal cancer, short-term efficacy, concurrent chemo-radiotherapy

中图分类号:

R735.1

焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.

JIAO Wenjing, GUO Xiujuan, MA Ming, SHAO Junguo, ZHANG Jinyan. Comparative efficacies between concurrent chemo-radiotherapy and radiotherapy alone in elderly patients with locally advanced esophageal cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 124-128.

参考文献

[1] 李丹凤, 李辉, 马晶晶, 等. 营养监测对老年食管癌术后病人生活质量的影响[J]. 实用老年医学, 2021, 35(1):20-23, 27.
[2] 姜建德, 宋保国, 李泽锋, 等. 同期放化疗联合区域性热疗治疗老年食管癌的临床研究[J]. 中华肿瘤防治杂志, 2009, 16(5):399-400.
[3] ANDERSON S E, MINSKY B D, BAINS M, et al. Combined modality chemoradiation in elderly oesophageal cancer patients[J]. Br J Cancer, 2007, 96(12):1823-1827.
[4] XING L G, LIANG Y M, ZHANG J D, et al. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer[J]. J Cancer Res Clin Oncol, 2014, 140(5):867-872.
[5] MOLENA D, STEM M, BLACKFORD A L, et al. Esophageal cancer treatment is underutilized among elderly patients in the USA[J]. J Gastrointest Surg, 2017, 21(1):126-136.
[6] HERSKOVIC A, MARTZ K, AL-SARRAF M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus[J]. N Engl J Med, 1992, 326(24):1593-1598.
[7] SONG G M, TIAN X, LIU X L, et al. Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer:evidence based on a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(23):37963-37973.
[8] RIZVI F H, SYED A A, KHATTAK S, et al. Complete pathological response after neoadjuvant treatment in locally advanced esophageal cancer predicts long term survival:a retrospective cohort study[J]. Int J Surg, 2014, 12(6):621-625.
[9] SCHEER R V, FAKIRIS A J, JOHNSTONE P A. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 80(4):996-1001.
[10] SERVAGI-VERNAT S, CRÉHANGE G, ROULLET B, et al. Phase Ⅱ study of a platinum-based adapted chemotherapy regimen combined with radiotherapy in patients 75 years and older with esophageal cancer[J]. Drugs Aging, 2015, 32(6):487-493.
[11] ZHAO Q, HU G, XIAO W, et al. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma:a retrospective cohort study[J]. Medicine:Baltimore, 2017, 96(35):e7920.
[12] LEE S J, AHN B M, KIM J G, et al. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer:a pilot study[J]. J Korean Med Sci, 2009, 24(1):120-125.
[13] 许涛, 景红霞, 曹风军, 等. 调强放疗联合替吉奥同步治疗非手术老年食管癌的临床疗效[J]. 中国老年学杂志, 2018, 38(5):1090-1093.
[14] 王利利, 王坚, 汪建林, 等. 老年食管癌患者单纯放疗和同步放化疗的临床研究[J]. 中华放射医学与防护杂志, 2018, 38(12):907-911.

[1]	张玉领, 陈培. 环状RNA在食管癌中的研究进展[J]. 癌变·畸变·突变, 2021, 33(3): 241-245.
[2]	张娜, 范志露, 杨荔艳, 常晨, 蔡岩, 郝佳洁, 王明荣. 食管鳞癌中SERPINB5表达降低的作用机制及其临床意义[J]. 癌变·畸变·突变, 2021, 33(2): 101-109.
[3]	陈婉娴, 王思梦, 陈张瑜, 王潘集, 郑淳文, 李恩民, 许丽艳. CDC42抑制剂CASIN对食管癌细胞活力与迁移能力的抑制作用[J]. 癌变·畸变·突变, 2021, 33(2): 136-142.
[4]	杨丽, 张孟贤, 张微, 熊英友, 陈世勇, 方呈祥. 基于数据挖掘分析极光激酶A在食管癌中的表达及意义[J]. 癌变·畸变·突变, 2020, 32(3): 221-228.
[5]	熊英友, 杨丽, 方呈祥, 吴倩, 张微, 赵毅, 文静. 数据挖掘分析SLC7A11在食管癌中的表达及通过P53/ROS通路调节细胞铁死亡的意义[J]. 癌变·畸变·突变, 2020, 32(2): 126-131.
[6]	封敏, 艾比拜·莫合塔尔, 石静怡, 祖可来·艾力江, 李永祥, 闫长顺, 李秀梅. 哈萨克族食管癌组织中miR-143、miR-145和Survivin mRNA的表达及其临床病理意义[J]. 癌变·畸变·突变, 2020, 32(1): 29-32.
[7]	马莉莉, 张树丽, 李琴, 许彭, 封敏, 李秀梅. 新疆哈萨克族食管癌与正常组织间差异表达miRNA的筛查及验证[J]. 癌变·畸变·突变, 2020, 32(1): 52-56.
[8]	孙晓男, 苑青, 杨荔艳, 张钰, 蔡岩, 徐昕, 王明荣, 郝佳洁, 贾雪梅. 成纤维细胞生长因子结合蛋白2过表达促进食管癌细胞的增殖[J]. 癌变·畸变·突变, 2019, 31(3): 180-185,192.
[9]	陈欣然, 宋永志, 单保恩. 协同刺激分子B7-H4在食管癌前病变组织中的表达及临床意义[J]. 癌变·畸变·突变, 2018, 30(5): 368-373.
[10]	杨兴肖, 邹乃祎, 李巧芳, 张雪原, 宋姮, 刘志坤, 马鸣, 单保恩, 祝淑钗. RNF2和PCNA在食管鳞状细胞癌中的表达及临床意义[J]. 癌变·畸变·突变, 2018, 30(4): 254-257.
[11]	陈欣然, 单保恩. 协同刺激分子B7-H4在小鼠食管癌前病变中的表达[J]. 癌变·畸变·突变, 2018, 30(4): 263-269,274.
[12]	何曙芝, 赵跃, 刘洋, 杨留才, 陈平, 刘冉. 盐城地区食管癌化疗患者近期生命质量评价[J]. 癌变·畸变·突变, 2017, 29(6): 437-444,449.
[13]	郑鑫林, 夏学阳, 张金周, 张建华, 李斌. 食管癌干细胞相关标记物及其分离和鉴定的研究进展[J]. 癌变·畸变·突变, 2016, 28(3): 246-249.
[14]	蔡晓曼, 陈素钻, 俞晶, 刘朝晖, 吴瑞暖, 汤盛新, 郭光华. 小窝蛋白-1和E-钙黏蛋白在食管癌TE1细胞系中的表达及其意义[J]. 癌变·畸变·突变, 2016, 28(3): 227-230.
[15]	高志奎, 刘冉, 尹立红, 浦跃朴. miR-338基因簇与食管癌发病风险的病例对照研究[J]. 癌变·畸变·突变, 2016, 28(2): 107-110.

老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较

Comparative efficacies between concurrent chemo-radiotherapy and radiotherapy alone in elderly patients with locally advanced esophageal cancers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价